Treatment Options for Nightmare Disorder in Adults Listed

A position paper at the American Academy of Sleep Medicine (AASM) listed out treatment options for nightmare disorder among adults and nightmares associated with post-traumatic stress disorder (PTSD). Although evidence was less clear for other treatments, the task force found that a variety of interventions may be used for the treatment of nightmare disorder, including cognitive behavioral therapy, hypnosis, and several prescription medications. In contrast, the task force concluded that the anti-anxiety medication clonazepam and the antidepressant venlafaxine are not recommended for the treatment of nightmare disorder.

"Helpful treatment options are available for adults who are experiencing distress due to nightmares," said lead author Dr. Timothy Morgenthaler, professor of medicine at Mayo Clinic in Rochester, Minnesota. "The judgment and expertise of a knowledgeable clinician are essential to ensure appropriate treatment selection and effective management of nightmare disorder."

A task force developed the position paper based on their clinical expertise and a qualitative assessment of the available evidence.

Nightmare disorder involves repeated occurrences of nightmares that cause clinically significant distress or impairment. It affects approximately 4 percent of adults, occurring in isolation or as part of other disorders such as PTSD, and it can significantly impair quality of life. Nightmare disorder also can exacerbate an underlying mental illness, such as depression or anxiety.

"The first step to get help for nightmares is to discuss this concern with a doctor, who may refer you to an accredited sleep center for a comprehensive sleep evaluation by a board-certified sleep medicine physician," said AASM President Dr. Douglas Kirsch. "Effectively treating nightmare disorder can improve sleep quality, resulting in less daytime sleepiness and improved alertness."

The position paper includes the following position statements. Positions of "recommended" and "not recommended" indicate that a treatment option is determined to be clearly useful, or ineffective or harmful, for most patients. Positions of "may be used" indicate that the evidence or expert consensus is less clear, either in favor, or against the use, of a treatment option:

• The following therapy is recommended for the treatment of PTSD-associated nightmares and nightmare disorder: image rehearsal therapy.
• The following therapies may be used for the treatment of PTSD-associated nightmares: cognitive behavioral therapy; cognitive behavioral therapy for insomnia; eye movement desensitization and reprocessing; exposure, relaxation, and rescripting therapy; the atypical antipsychotics olanzapine, risperidone and aripiprazole; clonidine; cyproheptadine; fluvoxamine; gabapentin; nabilone; phenelzine; prazosin; topiramate; trazodone; and tricyclic antidepressants.
• The following therapies may be used for the treatment of nightmare disorder: cognitive behavioral therapy; exposure, relaxation, and rescripting therapy; hypnosis; lucid dreaming therapy; progressive deep muscle relaxation; sleep dynamic therapy; self-exposure therapy; systematic desensitization; testimony method; nitrazepam; prazosin; and triazolam.
• The following are not recommended for the treatment of nightmare disorder: clonazepam and venlafaxine.
• The ultimate judgment regarding propriety of any specific care must be made by the clinician, in light of the individual circumstances presented by the patient, accessible treatment options, and resources.

The task force also identified a need for more randomized controlled trials and well-designed comparative efficacy trials to allow for further evaluation of treatments for nightmare disorder.

Advertisement

Source-Eurekalert